CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 ...

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare.

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

But ironically, the company has benefited from winning tenders to counter the impact of the avian flu pandemic which has ...

CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...

CSL has reported a 7% net profit rise for the December half, with its blood-derived products offsetting weak flu vaccination ...

Due to the planned CSL transition, Plasma revenue declined 9% in the quarter ... digital transformation costs and the timing of certain payments that occurred in our fiscal first quarter.

Greg Leyh likes to screw around with voltage and electric fields and plasma. In his time he's built some of the world's biggest Tesla coils, huge towering transformers that throw off terrifying webs ...

We believe CSL's valuation multiple de-rate is onerous considering the growth outlook, particularly for IG therapies. Key risks include: (1) US inflation impacting plasma donor fees, (2 ...

The US Treasury has sought to calm fears over Elon Musk’s access to its vast payments system, insisting no transactions have been cancelled, despite the billionaire’s claim to be “rapidly ...